SCHEMBL24927489

SCHEMBL24927489

N#Cc1ncc(N2CCCCCCCC2)nc1N

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.46
▸ ALDH1A1 P00352 4/20 0.46
▸ HPGD P15428 4/20 0.46
▸ POLB P06746 3/20 0.46
▸ MAPT P10636 3/20 0.46
▸ HSD17B10 Q99714 3/20 0.46
▸ L3MBTL1 Q9Y468 2/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ RAB9A P51151 2/20 0.46
▸ BLM P54132 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ RECQL P46063 2/20 0.46
▸ APAF1 O14727 1/20 0.46
▸ PLA2G1B P04054 1/20 0.46
▸ TP53 P04637 1/20 0.46
▸ HSP90AA1 P07900 1/20 0.46
▸ HSP90AB1 P08238 1/20 0.46
▸ THRB P10828 1/20 0.46
▸ CASP1 P29466 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16801718 0.81 BTK (0.50) KDM4EALDH1A1HPGDPOLBMAPT
SCHEMBL30905996 0.81 BTK (0.50) KDM4EALDH1A1HPGDPOLBMAPT
SCHEMBL21946731 0.81 BTK (0.50) KDM4EALDH1A1HPGDPOLBMAPT
SCHEMBL21855213 0.79 BTK (0.51) KDM4EALDH1A1HPGDL3MBTL1RAB9A
SCHEMBL18296315 0.73 PLAU (0.43) ALDH1A1MEN1RAB9AKMT2ATP53
SCHEMBL8896520 0.70 KDM4E (0.46) KDM4EALDH1A1HPGDPOLBHSD17B10
SCHEMBL18296104 0.69 PIK3CD (0.50) PIK3CD
SCHEMBL24242896 0.69 AR (0.49) ALDH1A1MAPTARLMNACNR2
SCHEMBL1143659 0.68 CSNK1A1 (0.49) KDM4EALDH1A1HPGDPOLBHSD17B10
SCHEMBL25528684 0.68 SMN1; SMN2 (0.41) KDM4EALDH1A1HPGDMAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230029378-A1 BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY NURIX THERAPEUTICS, INC. 2023-01-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230029378-A1 BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY CBL, XIAP, BTK KDM4E 1022/4885ALDH1A1 4160/4885HPGD 3787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback